Literature DB >> 20938626

[Multimodality treatment for hepatocellular carcinoma].

N P Malek1, A Vogel, M P Manns.   

Abstract

Hepatocellular carcinoma represents one of the most important tumor entities worldwide. The great majority of these cases in Germany can be attributed to chronic liver disease (alcohol, viral hepatitis among others), which lead to development of liver cirrhosis and ultimately to hepatocellular carcinoma. While our understanding of the pathophysiological principles underlying the origin of hepatocellular carcinoma has increased considerably in recent years, the prognosis of the majority of these patients remains poor. However, a combined interdisciplinary approach involving internists, surgeons, and radiologists can often achieve effective palliative treatment of the disease. This has recently been reinforced by applying systemic therapies which specifically influence the important biological processes of hepatocellular carcinoma. It can be assumed that by adhering to well-defined treatment algorithms and using improved drug therapy the prognosis of patients with this form of cancer will improve in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938626     DOI: 10.1007/s00108-010-2673-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

Review 1.  Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Authors:  Nicholas J Petrelli; Eric P Winer; Julie Brahmer; Sarita Dubey; Sonali Smith; Charles Thomas; Linda T Vahdat; Jennifer Obel; Nicholas Vogelzang; Maurie Markman; John W Sweetenham; David Pfister; Mark G Kris; Lynn M Schuchter; Raymond Sawaya; Derek Raghavan; Patricia A Ganz; Barnett Kramer
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

2.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

4.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

7.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

8.  Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends.

Authors:  Peter Jepsen; Hendrik Vilstrup; Robert E Tarone; Søren Friis; Henrik Toft Sørensen
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

9.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

Authors:  Melanie B Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Thomas Brown; Asif Rashid; Janet Dancey; James L Abbruzzese
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.